Real acupuncture vs sham acupuncture produced more meaningful cognitive outcomes among patients with breast cancer.
Spencer Feldman
Advertisement
Articles by Spencer Feldman
Overall survival data in the IMbrave152/SKYSCRAPER-14 study are not anticipated to show statistical significance.
Patients with neuropathy experienced a longer PFS with enfortumab vedotin vs those without neuropathy, skin rash, or hyperglycemia.
The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.
Time to next treatment was slightly higher with elacestrant for patients with HR+/HER2–, ESR1-mutant breast cancer vs PFS in a phase 3 trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
5